Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

Status Terminated

Clinical Trial Summary

The primary aim of this study is to evaluate the effect of Exendin (9-39) on glucose requirements to maintain euglycemia in pediatric patients with congenital hyperinsulinism (CHI) who have failed medical therapy. The secondary aims are to determine the therapeutic plasma levels, plasma half-life and pharmacokinetics of Exendin (9-39) during a 9-hour intravenous infusion.

Clinical Trial Description

This study will enroll infants with congenital hyperinsulinism owing to KATP channel mutations who are unresponsive to medical therapy and will require a pancreatectomy to control hypoglycemia from a single academic medical center in the United States.

An open-label, two-period, two-treatment crossover study design with a dose-escalation component will be implemented. Successive cohorts of patients (up to 5 participants/cohort) will each receive a fixed dose of Exendin (9-39) infusion and normal saline vehicle on two separate days in random order. The protocol specifies 0.02 mg/kg/hr, via continuous intravenous infusion, administered over 9-hours for the first cohort. The volume of saline to be infused will be calculated to match the volume of Exendin (9-39). Successive cohorts will be given doses that are increased in up to 1/2 log increments. Overall, the investigators hypothesize that antagonism of the GLP-1 receptor by Exendin (9-39) will increase fasting blood glucose levels, prevent protein-induced hypoglycemia and decrease glucose requirement to maintain euglycemia in infants with CHI.

Aim 1. To examine the effect of Exendin (9-39) on glucose requirements to maintain euglycemia in infants with congenital hyperinsulinism unresponsive to medical therapy.

Aim 2. To determine therapeutic plasma levels, plasma half-life and pharmacokinetics of Exendin-(9-39) during an intravenous infusion. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00835328
Study type	Interventional
Source	Children's Hospital of Philadelphia
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	August 26, 2009
Completion date	January 28, 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02021604` - Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma	Phase 1
Recruiting	`NCT04732416` - HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)	Phase 2
Completed	`NCT02937558` - CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism	Phase 2
Completed	`NCT02604485` - A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism	Phase 2
Recruiting	`NCT04205604` - 18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism	Phase 2
Completed	`NCT00897676` - Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity	Phase 1/Phase 2
Completed	`NCT00987168` - Sandostatine® LP and Hyperinsulinism	Phase 2
Active, not recruiting	`NCT03941236` - Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism	Phase 3
Completed	`NCT03042416` - 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety	Phase 3
Completed	`NCT04172441` - Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism	Phase 2/Phase 3
Recruiting	`NCT04706910` - 18F-DOPA II - PET Imaging Optimization	Phase 3
Recruiting	`NCT06208215` - RZ358 Treatment for Congenital Hyperinsulinism	Phase 3
Completed	`NCT03777176` - A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism	Phase 3
Recruiting	`NCT03768518` - GLP-1 Receptor Expression in CHI
Completed	`NCT04538989` - An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism	Phase 2
Completed	`NCT01070758` - Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy	Phase 4
Completed	`NCT00674440` - Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism	Phase 2
Completed	`NCT00571324` - Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism	Phase 1/Phase 2
Withdrawn	`NCT03053284` - Pasireotide in Hyperinsulinemic Hypoglycemia	Phase 2
No longer available	`NCT02533219` - Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia